Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CLVLY Relative to the S&P 500

CLVLY Relative to the Sector

Seasonal Chart Analysis

Analysis of the Clinuvel Pharmaceuticals Ltd. (OTCMKT:CLVLY) seasonal charts above shows that a Buy Date of September 28 and a Sell Date of January 13 has resulted in a geometric average return of 5.8% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 14.46% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.

To download CLVLY seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CLVLY